ReviewNature reviews. Immunology2016
Immune responses and immunopathology in acute and chronic viral hepatitis.
Review in Nature reviews. Immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 191 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B: A Multicenter, Real-world Study
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
Who cites it
191 citing papers in PubMed, 353 citations in OpenAlex.
- Trial
- ANKRD11 deficiency reprograms CD8Nature immunology · 2026Article
- Cirrhosis Impairs Reconstitution of the Circulating T-Lymphocyte Compartment After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.United European gastroenterology journal · 2026Article
- Natural killer cells against viral infection: from basic biology to immunotherapy.Precision clinical medicine · 2026Review
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- HCV-Induced Hepatocarcinogenesis: Molecular Mechanisms, Persistent Cancer Risk, and Future Perspectives.Biomedicines · 2026Review
- Excitability as a design principle in the immune system.Science advances · 2026Article
- Chemical suppression of a bacterial immune system revives repressed phages.bioRxiv : the preprint server for biology · 2026Article
- Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.Signal transduction and targeted therapy · 2026Review
- COVID-19 vaccine immunogenicity in Mongolian adults with and without chronic hepatitis.BMC infectious diseases · 2026Article
- Article
- mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress.Molecular therapy. Nucleic acids · 2026Review
- Nanoparticle approaches for hepatitis therapy and clinical translation.Discover nano · 2026Review
- Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood - Clinical, Virological and Immunological Long-Term Follow-Up.Journal of viral hepatitis · 2026Article
- Spontaneous Recovery from Hepatitis A-Induced Acute Liver Failure in a Child: A Rare Case Report from Hargeisa Group Hospital, Somaliland.International medical case reports journal · 2026Article
- Tissue-resident memory CD8Nature reviews. Gastroenterology & hepatology · 2025Review
- Virological and immunological determinants of hepatitis E virus infection outcomes.Current opinion in virology · 2025Review
- Integrated multiomics reveals host-virus coadaptation in persistent foot-and-mouth disease virus infection.Cellular and molecular life sciences : CMLS · 2025Article
- Natural killer cells and IFN-γ protect against liver injury during HAV infection in mice.Journal of virology · 2025Article
- "Recommendations for clinical study protocols for immune and inflammatory profiling in Parkinson's disease".NPJ Parkinson's disease · 2025Review
131 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) are responsible for most cases of viral hepatitis. Infection by each type of virus results in a different typical natural disease course and clinical outcome that are determined by virological and immunological factors. HCV tends to establish a chronic persistent infection, whereas HAV does not. HBV is effectively controlled in adults, although it persists for a lifetime after neonatal infection. In this Review, we discuss the similarities and differences in immune responses to and immunopathogenesis of HAV, HBV and HCV infections, which may explain the distinct courses and outcomes of each hepatitis virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.